Payment overview · 2025
General Payments
$203.20
9 reported records · 7 companies
Healthcare provider profile · identity verified
Grant D Sievertsen, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism · HINSDALE, IL · NPI 1134197619
Verified facts
What the public records show
CMS Open Payments records show Grant D Sievertsen, MD received $203.20 in general payments during 2025 across 9 reported records.
PFIZER INC. accounted for 24.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Ozempic, Rybelsus.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 151 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 151 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 206 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 153 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $48.93 | 24.1% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $38.12 | 18.8% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $28.33 | 13.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $27.91 | 13.7% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $21.53 | 10.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.72 | 9.7% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.66 | 9.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $203.20 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $48.93 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $48.93 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $28.33 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $28.33 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $27.91 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $21.53 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $19.72 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $19.72 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $19.53 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.66 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.59 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.59 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 153 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 151 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 206 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 66 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
151 | 33 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
151 | 33 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
45 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
206 | 49 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
66 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
153 | 34 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1242 | 309 |
| Atorvastatin Calcium | Atorvastatin Calcium | 767 | 209 |
| Amlodipine Besylate | Amlodipine Besylate | 649 | 188 |
| Metformin Hcl | Metformin Hcl | 572 | 162 |
| Glimepiride | Glimepiride | 547 | 137 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 400 | 131 |
| Losartan Potassium | Losartan Potassium | 393 | 120 |
| Simvastatin | Simvastatin | 351 | 100 |
| Lisinopril | Lisinopril | 332 | 97 |
| Metoprolol Succinate | Metoprolol Succinate | 306 | 91 |
| Omeprazole | Omeprazole | 281 | 79 |
| Hydrochlorothiazide | Hydrochlorothiazide | 246 | 67 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 240 | 76 |
| Ozempic | Semaglutide | 206 | 49 |
| Allopurinol | Allopurinol | 193 | 57 |
| Furosemide | Furosemide | 180 | 62 |
| Pantoprazole Sodium | Pantoprazole Sodium | 177 | 66 |
| Tamsulosin Hcl | Tamsulosin Hcl | 173 | 54 |
| Alprazolam | Alprazolam | 169 | 48 |
| Synthroid | Levothyroxine Sodium | 156 | 42 |
| Eliquis | Apixaban | 153 | 34 |
| Jardiance | Empagliflozin | 151 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 150 | 44 |
| Metformin Hcl Er | Metformin Hcl | 125 | 31 |
| Sertraline Hcl | Sertraline Hcl | 122 | 39 |
| Trazodone Hcl | Trazodone Hcl | 107 | 35 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 106 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 102 | 24 |
| Methimazole | Methimazole | 97 | 28 |
| Gabapentin | Gabapentin | 94 | 35 |
| Potassium Chloride | Potassium Chloride | 94 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 78 | 25 |
| Humalog Kwikpen U-100 | Insulin Lispro | 75 | 31 |
| Donepezil Hcl | Donepezil Hcl | 73 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 72 | 22 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 69 | 27 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 66 | 20 |
| Novolog Flexpen | Insulin Aspart | 66 | 23 |
| Rybelsus | Semaglutide | 66 | 11 |
| Tramadol Hcl | Tramadol Hcl | 64 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 60 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 59 | 21 |
| Ezetimibe | Ezetimibe | 57 | 21 |
| Irbesartan | Irbesartan | 55 | 13 |
| Atenolol | Atenolol | 52 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 51 | 20 |
| Glipizide | Glipizide | 50 | 15 |
| Carvedilol | Carvedilol | 49 | 15 |
| Glipizide Er | Glipizide | 49 | suppressed |
| Clonazepam | Clonazepam | 48 | 11 |
| Diazepam | Diazepam | 46 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 46 | 15 |
| Warfarin Sodium | Warfarin Sodium | 46 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 45 | 41 |
| Divalproex Sodium | Divalproex Sodium | 45 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 45 | suppressed |
| Trulicity | Dulaglutide | 45 | 11 |
| Finasteride | Finasteride | 44 | 12 |
| Amiodarone Hcl | Amiodarone Hcl | 42 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 42 | 16 |
| Meloxicam | Meloxicam | 42 | 18 |
| Enalapril Maleate | Enalapril Maleate | 41 | 11 |
| Spironolactone | Spironolactone | 40 | 13 |
| Azithromycin | Azithromycin | 39 | 36 |
| Methylprednisolone | Methylprednisolone | 39 | 34 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 35 | 15 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 35 | 22 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 35 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 34 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 34 | suppressed |
| Humalog | Insulin Lispro | 33 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 33 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 32 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 31 | 11 |
| Pregabalin | Pregabalin | 31 | 18 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 29 | 11 |
| Ramipril | Ramipril | 29 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 28 | suppressed |
| Testosterone | Testosterone | 27 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 26 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | suppressed |
| Amoxicillin | Amoxicillin | 25 | 19 |
| Terbinafine Hcl | Terbinafine Hcl | 25 | suppressed |
| Valsartan | Valsartan | 25 | suppressed |
| Trueplus Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | 15 |
| Methenamine Hippurate | Methenamine Hippurate | 22 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 22 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Levofloxacin | Levofloxacin | 21 | 18 |
| Lorazepam | Lorazepam | 21 | suppressed |
| Prednisone | Prednisone | 21 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 19 | suppressed |
| Novolog | Insulin Aspart | 19 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 17 |
| Estradiol | Estradiol | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 18 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 18 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 16 | suppressed |
| Eplerenone | Eplerenone | 16 | suppressed |
| Famotidine | Famotidine | 16 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 16 | suppressed |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | 12 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 15 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Cefadroxil | Cefadroxil | 14 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 14 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Cabergoline | Cabergoline | 12 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Mounjaro | Tirzepatide | 11 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 11 | suppressed |
| Zaleplon | Zaleplon | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $203.20 · 9 records | PFIZER INC. | AIRSUPRA, AREXVY, ELIQUIS, JARDIANCE, MOUNJARO, NURTEC ODT, Ozempic, Rybelsus, SHINGRIX, The Cologuard Plus Collection Kit, Wegovy, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error